JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis

Phase 2 Completed 78 enrolled French Innovative Leukemia Organisation

NaSingle-groupOpen-labelTreatment

Summary

JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with primary or secondary myelofibrosis : a prospective phase II

Timeline

Start: 2012-12
Primary completion: 2018-05
Completion: 2019-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolotinib	Unknown	—	—

JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis

Summary

Timeline

Drugs

Indications